Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tipiracil/trifluridine - Taiho Pharmaceutical

Drug Profile

Tipiracil/trifluridine - Taiho Pharmaceutical

Alternative Names: FTD/TPI; Lonsurf; Orcantas; S 95005; S 95005/TAS-102; T15, T20; T15/T20; TAS-102; TAS-102/S-95005; Tipiracil-hydrochloride/trifluridine; Trifluridine/tipiracil; Trifluridine/tipiracil hydrochloride

Latest Information Update: 17 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Taiho Pharmaceutical
  • Developer Amgen; Emory University; Ipsen; PharmaEngine; Servier; Taiho Pharmaceutical; TTY Biopharm; University of Florida; University of Wisconsin-Madison
  • Class Antineoplastics; Nucleosides; Pyrimidines; Pyrrolidines; Small molecules
  • Mechanism of Action DNA synthesis inhibitors; Thymidine phosphorylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Colorectal cancer; Gastric cancer
  • Phase II Bladder cancer; Cholangiocarcinoma; Oesophageal cancer; Pancreatic cancer; Small cell lung cancer
  • Phase I/II Gastrointestinal cancer
  • Phase I Neuroendocrine tumours; Solid tumours

Most Recent Events

  • 15 Oct 2019 Efficacy data from the phase III TAS-102 trial in Gastric or gastroesophageal junction cancer released by Taiho Oncology
  • 09 Sep 2019 Registered for Colorectal cancer (Metastatic disease, Second-line therapy or greater) in China (PO)
  • 06 Sep 2019 Registered for Gastric cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in Liechtenstein (PO), Iceland (PO), Norway (PO), European Union (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top